Holding(s) in Company

RNS Number : 2637G

N4 Pharma PLC

16 March 2020

 

16 March 2020

N4 Pharma plc

("N4 Pharma", the "Company" or the "Group")

Holding in Company

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has been notified today that, as of 26 July 2019, First Equity Limited no longer had a notifiable interest in the issued share capital of the Company.

Enquiries:

N4 Pharma Plc Nigel Theobald, CEO	Via Scott PR
Allenby Capital Limited James Reeve/Asha Chotai	Tel: [phone]
Scott PR Georgia Smith	Tel: [phone]

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

END

 

 

HOLFLFFIVFIRLII